4.4 Article

Impact of EGFR and EGFR ligand expression on treatment response in patients with metastatic colorectal cancer

期刊

ONCOLOGY LETTERS
卷 21, 期 6, 页码 -

出版社

SPANDIDOS PUBL LTD
DOI: 10.3892/ol.2021.12709

关键词

epidermal growth factor; epidermal growth factor receptor; epidermal growth factor receptor ligands; cetuximab; colorectal cancer; liver metastases; prognosis; response

类别

资金

  1. Olympia-Morata Postdoctoral Fellowship of the Medical Faculty of the University of Heidelberg (Heidelberg, Germany)

向作者/读者索取更多资源

The study investigated the association between the expression of EGFRs and their ligands in tumors with response to cetuximab therapy in mCRC patients. However, the results showed that there was no significant correlation between the expression levels of EGFRs and their ligands with the treatment response. Therefore, EGFR or EGFR ligand expression does not predict treatment response in CRC patients with liver metastases following cetuximab therapy.
Up to 50% of patients with colorectal cancer (CRC) have either synchronous or metachronous hepatic metastases in the course of their disease. Patients with metastatic CRC (mCRC) whose tumors express wild-type KRAS benefit from treatment with monoclonal antibodies (such as cetuximab or panitumumab) that target the epidermal growth factor receptor (EGFR). However, the therapeutic response to these antibodies is variable, and further predictive models are required. The present study examined whether expression of different EGFRs or their ligands in tumors was associated with the response to cetuximab treatment. Tumor tissues, collected during liver resection in 28 patients with mCRC, were analyzed. The protein expression levels of EGFR/ErbB1, ErbB2, ErbB3 and the EGFR ligands heregulin and amphiregulin were determined using Luminex 200(R) and enzyme-linked immunosorbent assays. Computed tomography or magnetic resonance imaging was performed 4 weeks before and 6-8 weeks after treatment with cetuximab. Response to treatment was assessed using the response evaluation criteria for solid tumors (RECIST). The association between the protein expression levels of different EGFRs and their ligands with RECIST criteria was then analyzed to determine whether these protein levels could predict the treatment response to cetuximab. A total of 12 patients exhibited a partial response, 9 exhibited stable disease and 7 exhibited progressive disease after cetuximab therapy according to RECIST. The expression levels of EGFRs (EGFR/ErbB1, ErbB2 and ErbB3) and their ligands (heregulin and amphiregulin) were not significantly associated with the response to cetuximab therapy. Therefore, the present study indicated that EGFR or EGFR ligand expression did not predict treatment response in patients with CRC with liver metastases following cetuximab therapy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据